Top

Published in:

Open Access 01-12-2011 | Short report

International Conference on Advances in Radiation Oncology (ICARO): Outcomes of an IAEA Meeting

Authors: Eeva K Salminen, Krystyna Kiel, Geoffrey S Ibbott, Michael C Joiner, Eduardo Rosenblatt, Eduardo Zubizarreta, Jan Wondergem, Ahmed Meghzifene

Published in: Radiation Oncology | Issue 1/2011

Abstract

The IAEA held the International Conference on Advances in Radiation Oncology (ICARO) in Vienna on 27-29 April 2009. The Conference dealt with the issues and requirements posed by the transition from conventional radiotherapy to advanced modern technologies, including staffing, training, treatment planning and delivery, quality assurance (QA) and the optimal use of available resources. The current role of advanced technologies (defined as 3-dimensional and/or image guided treatment with photons or particles) in current clinical practice and future scenarios were discussed.

ICARO was organized by the IAEA at the request of the Member States and co-sponsored and supported by other international organizations to assess advances in technologies in radiation oncology in the face of economic challenges that most countries confront. Participants submitted research contributions, which were reviewed by a scientific committee and presented via 46 lectures and 103 posters. There were 327 participants from 70 Member States as well as participants from industry and government. The ICARO meeting provided an independent forum for the interaction of participants from developed and developing countries on current and developing issues related to radiation oncology.

Adams EJ, Warrington AP: A comparison between cobalt and linear accelerator-based treatment plans for conformal and intensity-modulated radiotherapy. Br J Radiol 2008, 81: 304-10. 10.1259/bjr/77023750CrossRefPubMed

Rachivandran R: Has the time come for doing away with Cobalt-60 teletherapy for cancer treatments? J Med P 2009, 34: 63-5. 10.4103/0971-6203.51931CrossRef

Vikram B, Coleman CN, Deye JA: Current status and future potential of advanced technologies in radiation oncology. Part 1: Challenges and resources. Oncology 2009, 23: 279-83.PubMed

Vikram B, Coleman CN, Deye JA: Current status and future potential of advanced technologies in radiation oncology. Part 2: State of the science by anatomic site. Oncology 2009, 23: 380-5.PubMed

Veldeman L, Madani I, Hulstaert F, De Meerleer G, Mareel M, De Neve W: Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies. Lancet Oncol 2008, 9: 367-375. 10.1016/S1470-2045(08)70098-6CrossRefPubMed

Rothschild S, Studer G, Seifert B, Huguenin P, Glanzmann C, Davis JB, Lütolf UM, Hany TF, Ciernik IF: PET/CT with intensity modulated radiotherapy (IMRT) improves treatment outcome of locally advanced pharyngeal carcinoma: a matched-pair analysis. Radiation Oncology 2007, 2: 22. 10.1186/1748-717X-2-22PubMedCentralCrossRefPubMed

Zelefsky MJ, Fuks Z, Happersett L, Lee HJ, Ling CC, Burman CM, Hunt M, Wolfe T, Venkatraman ES, Jackson A, Skwarchuk M, Leibel SA: Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol 2000,55(3):241-249. 10.1016/S0167-8140(99)00100-0CrossRefPubMed

Pignol J, Olivotto I, Rakovitch E, Gardner S, Ackerman I, Sixel K, Beckham W, Vu T, Chow E, Paszat L: Phase III randomized study of intensity modulated radiation therapy versus standard wedging technique for adjuvant breast radiotherapy. Int J Radiat Oncol Biol Phys 2006,66(3 Suppl 1):S1.CrossRef

Donovan E, Beakley N, Denholm E, Evans P, Gothard L, Hanson J, Peckitt C, Reise S, Ross G, Sharp G, Symonds-Tayler R, Tait D, Yarnold J: Randomised trial of standard 2D radiotherapy versus intensity modulated radiation therapy (IMRT) in patients prescribed breast radiotherapy. Radiother Oncol 2007, 82: 254-64. 10.1016/j.radonc.2006.12.008CrossRefPubMed

10.

Mell LK, Mehrotra AK, Mundt AJ: Intensity-modulated radiation therapy use in the U.S. 2004. Cancer 2005, 104: 1296-1303. 10.1002/cncr.21284CrossRefPubMed

11.

Van Herk M: Different styles of Image-Guided Radiotherapy. Semin Radiat Oncol 2007,17(4):258-267. 10.1016/j.semradonc.2007.07.003CrossRefPubMed

12.

Simpson DR, Lawson JD, Nath SK, Rose BS, Mundt AJ, Mell LK: A survey of image-guided radiation therapy use in the United States. Cancer 2010,116(16):3953-60. 10.1002/cncr.25129PubMedCentralCrossRefPubMed

13.

Shortt K, Davidson L, Hendry J, Dondi M, Andreo P: International perspectives on quality assurance and new techniques in radiation medicine: outcome of an IAEA conference. Int J Radiat Oncol Biol Phys 2008,71(Suppl 1):S80-S84.CrossRefPubMed

14.

Timmerman RD: An overview of hypofractionation and introduction to this issue of Seminars in Radiation Oncology. Semin Radiat Oncol 2008, 18: 215-222. 10.1016/j.semradonc.2008.04.001CrossRefPubMed

15.

Dewar JA, Haviland JS, Agrawal RK, Bliss JM, Hopwood P, Magee B, Owen JR, Sydenham MA, Venables K, Yarnold JR: Hypofractionation for early breast cancer: first results of the UK standardisation of breast radiotherapy (START) trials [abstract]. J Clin Oncol 2007, 25: LBA518.

16.

Whelan TJ, Kim DH, Sussman J: Clinical experience using hypofractionated radiation schedules in breast cancer. Semin Radiat Oncol 2008, 18: 257-264. 10.1016/j.semradonc.2008.04.008CrossRefPubMed

17.

Ritter M: Rationale, conduct and outcome using hypofractionated radiotherapy in prostate cancer. Semin Radiat Oncol 2008, 18: 249-256. 10.1016/j.semradonc.2008.04.007PubMedCentralCrossRefPubMed

18.

Brenner DJ: Hypofractionation for prostate cancer: what are the issues? Int J Radiat Oncol Biol Phys 2003, 57: 912-4. 10.1016/S0360-3016(03)01456-1CrossRefPubMed

19.

Nedzi LA: The implementation of ablative hypofractionated radiotherapy for stereotactic treatments in the brain and body: observations on efficacy and toxicity in clinical practice. Semin Radiat Oncol 2008, 18: 265-272. 10.1016/j.semradonc.2008.04.009CrossRefPubMed

20.

Schultz-Ertner D, Jäkel O, Schlegel W: Radiation therapy with charged particles. Semin Radiat Oncol 2006, 16: 249-259. 10.1016/j.semradonc.2006.04.008CrossRef

21.

Shipley WU, Verhey LJ, Munzenrider JE, Suit HE, Urie MM, McManus PL, Young RH, Shipley JW, Zietman AL, Biggs PJ, Heney NM, Goitein M: Advanced prostate cancer: the results of a randomized comparative trial of high-dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys 1995, 32: 3-12. 10.1016/0360-3016(95)00063-5CrossRefPubMed

22.

Talcott JA, Rossi C, William UC, Slater JD, Niemirenko A, Zietman AL: Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer. JAMA 2010,303(11):1046-53. 10.1001/jama.2010.287CrossRefPubMed

23.

Slater JD, Yonemoto LT, Rossi CJ: Conformal proton therapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 1998, 42: 299-304.CrossRefPubMed

24.

Akakura K, Tsujii H, Morita S: Phase I/II clinical trials on carbon ion therapy for prostate cancer. Prostate 2004, 58: 252-258. 10.1002/pros.10328CrossRefPubMed

25.

Hanks GE, Hanlon AL, Pinover WH: Dose escalation for prostate cancer patients based on dose comparison and dose-response studies. Int J Radiat Oncol Biol Phys 2000, 46: 823-832. 10.1016/S0360-3016(99)00498-8CrossRefPubMed

26.

Baltas D, Lymperopoulou G, Zamboglou M: On the use of HDR cobalt-60 source with the Mammosite radiation therapy system. Med Physics 2008, 35: 5263-5268. 10.1118/1.3002312CrossRef

27.

Ballester F, Granero D, Perez-Calatayud J, Casal E, Agramunt S, Cases R: Monte Carlo dosimetric study of the BEBI G Co-60 HDR source. Phys Med Biol 2005, 50: N309-N316. 10.1088/0031-9155/50/21/N03CrossRefPubMed

28.

Granero D, Perez-Calatayud J, Ballester F: Technical note: dosimetric study of a new Co-60 source used in brachytherapy. Med Physics 2007, 34: 3485-3488. 10.1118/1.2759602CrossRef

29.

Richter J, Baier K, Flentje M: The use of Co-60 sources for afterloading alternate to Ir-192 sources. In IFMBE Proceedings. World Congress on Medical Physics and Biomedical Engineering. Seoul Korea; 2006:1726-1730.

30.

Ntekim A, Adenipekun A, Akinlade B, Campbell O: High Dose Rate Brachytherapy in the Treatment of cervical cancer: preliminary experience with cobalt 60 Radionuclide source-A Prospective Study. Clin Med Insights Oncol 2010, 4: 89-94. 10.4137/CMO.S5269PubMedCentralCrossRefPubMed

31.

Haie-Meder C, Pötter R, Van Limbergen E, Briot E, De Brabandere M, Dimopoulos J, Dumas I, Helleburst TP, Kirisits C, Lang S, Muschitz S, Nevinson J, Nulens A, Petrow P, Wachster-Gerstner N: Recommendations from gynecologal GEC-ESTRO working-group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol 2005, 74: 235-245. 10.1016/j.radonc.2004.12.015CrossRefPubMed

32.

Pötter R, Haie-Meder C, Van-Limbergen E, Barillot I, De Brabandere M, Dimopoulos J, Dumas I, Erickson B, Lang S, Nulens A, Petrow P, Rownd J, Kirisits C: Recommendations from gynaecological GEC-ESTRO working-group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy - 3D dose-volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol 2006, 78: 67-77.CrossRefPubMed

33.

Viswanathan AN, Erickson BA: Three-dimensional imaging in gynecologic brachytherapy: a survey of the American Brachytherapy Society. Intl J Radiat Oncol Biol Phys 2010,76(1):104-9. 10.1016/j.ijrobp.2009.01.043CrossRef

34.

Vicini FA, Kini VR, Edmundson G, Gustafson GS, Stromberg J, Martinez AA: A comprehensive review of prostate cancer brachytherapy: defining an optimal technique. Int J Radiat Oncol Biol Phys 1999, 44: 483-491. 10.1016/S0360-3016(99)00047-4CrossRefPubMed

35.

Rosenthal SA, Bittner NH, Beyer DC, Demanes J, Goldsmith BJ, Horwitz EM, Ibbott GS, Lee WR, Nag S, Suh WW, Potters L: American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) Practice Guideline for the Transperineal Permanent Brachytherapy of Prostate Cancer. Int J Radiat Oncol Biol Phys 2011, 79: 335-341. 10.1016/j.ijrobp.2010.08.045CrossRefPubMed

36.

Battermann JJ, Boon TA, Moerland MA: Results of permanent prostate brachytherapy, 13 years of experience at a single institution. Radiother Oncol 2004, 71: 23-28. 10.1016/j.radonc.2004.01.020CrossRefPubMed

37.

Galalae RM, Martinez A, Mate T, Mitchell C, Edmunson G, Nuernberg N, Eulau S, Gustafson G, Gribble M, Kovacs G: Long-term outcome by risk factors using conformal high dose rate brachytherapy boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys 2004, 58: 1048-2055. 10.1016/j.ijrobp.2003.08.003CrossRefPubMed

38.

Pellizzon AC, Fogaroli RC, Gobo Silva ML, Guedes Castro D, Conte Maia M: Neoadjuvant Androgen Deprivation and Long-Term Results for Patients with Intermediate- and High-Risk Prostate Cancer Treated with High-Dose Rate Brachytherapy and External Beam Radiotherapy. Applied Cancer Research 2010, 30: 306-312.

39.

Martinez AA, Pataki I, Edmundson G, Sebastian E, Brabbins D, Gustafson G: Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: A feasibility report. Int J Radiat Oncol Biol Phys 2001, 49: 61-69. 10.1016/S0360-3016(00)01463-2CrossRefPubMed

40.

Staff requirements for a radiotherapy programme: Setting up a radiotherapy programme: clinical, medical physics, radiation protection and safety aspects. International Atomic Energy Agency, Vienna; 2008:17-31.

41.

IAEA Human Health: Resources and learning for health professionals.[http://nucleus.iaea.org/HHW/RadiationOncology/Makingthecaseforradiotherapyinyourcountry/Roleofradiotherapyincancercare/Radiotherapyisacosteffectivesystemwhichneedsabalance/index.html]

42.

Hayman JA, Hillner BE, Harris JR, Weeks JC: Cost-effectiveness of routine radiation therapy following conservative surgery for early-stage breast cancer. JCO 1998, 16: 1022-1029.

43.

Prieto L, Sacristan JA: Problems and solutions in calculating quality-adjusted life years (QUALYs). Health and Quality of Life Outcomes 2003, 1: 80. [http://www.hqlo.com/content/1/1/80] 10.1186/1477-7525-1-80PubMedCentralCrossRefPubMed

44.

Bleichrodt H, Quiggin J: Life-cycle preferences over consumption and health: when is cost-effectiveness analysis equivalent to cost-benefit analysis? J Health Econ 1999,18(6):681-708. 10.1016/S0167-6296(99)00014-4CrossRefPubMed

45.

IAEA Progrramme of Action for Cancer Therapy: cutting cancer treatment costs to save more lives[http://cancer.iaea.org/newsstory.asp?id=76]

Title: International Conference on Advances in Radiation Oncology (ICARO): Outcomes of an IAEA Meeting
Authors: Eeva K Salminen
Krystyna Kiel
Geoffrey S Ibbott
Michael C Joiner
Eduardo Rosenblatt
Eduardo Zubizarreta
Jan Wondergem
Ahmed Meghzifene
Publication date: 01-12-2011
Publisher: BioMed Central
Published in: Radiation Oncology / Issue 1/2011
Electronic ISSN: 1748-717X
DOI: https://doi.org/10.1186/1748-717X-6-11

Keynote webinar | Spotlight on medication adherence

Springer Medicine

International Conference on Advances in Radiation Oncology (ICARO): Outcomes of an IAEA Meeting

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

Intensity modulated or fractionated stereotactic reirradiation in patients with recurrent nasopharyngeal cancer

Endometrial cancer - reduce to the minimum. A new paradigm for adjuvant treatments?

Biological in-vivo measurement of dose distribution in patients' lymphocytes by gamma-H2AX immunofluorescence staining: 3D conformal- vs. step-and-shoot IMRT of the prostate gland

Gemcitabine/cisplatin versus 5-fluorouracil/mitomycin C chemoradiotherapy in locally advanced pancreatic cancer: a retrospective analysis of 93 patients

Commissioning and early experience with a new-generation low-energy linear accelerator with advanced delivery and imaging functionalities

Survival rate in nasopharyngeal carcinoma improved by high caseload volume: a nationwide population-based study in Taiwan